本文關(guān)鍵詞： 內(nèi)皮抑素 子宮內(nèi)膜癌 凋亡 聚腺苷二磷酸核糖聚合酶- 胱天蛋白酶-　出處：《中國(guó)臨床藥理學(xué)雜志》2017年20期 　論文類型：期刊論文

【摘要】：目的研究?jī)?nèi)皮抑素對(duì)子宮內(nèi)膜癌HEC1B細(xì)胞增殖、凋亡及其對(duì)聚腺苷二磷酸核糖聚合酶-1(PARP-1)和胱天蛋白酶-3(Caspase-3)表達(dá)的影響。方法用終濃度為10,50,100,200 mmol·L~(-1)的內(nèi)皮抑素干預(yù)的子宮內(nèi)膜癌HEC1B細(xì)胞為實(shí)驗(yàn)組,無(wú)任何藥物處理的子宮內(nèi)膜癌HEC1B細(xì)胞為對(duì)照組。培養(yǎng)48,72 h后,用噻唑藍(lán)(MTT)比色法檢測(cè)各組子宮內(nèi)膜癌HEC1B細(xì)胞增殖情況。用Hoechst33258熒光染色法檢測(cè)子宮內(nèi)膜癌HEC1B細(xì)胞凋亡情況;用酶聯(lián)免疫吸附(ELISA)法檢測(cè)子宮內(nèi)膜癌HEC1B細(xì)胞培養(yǎng)上清液中PARP-1和Caspase-3表達(dá)情況。結(jié)果對(duì)照組48,72 h細(xì)胞增殖抑制率分別為(6.24±0.39)%,(5.63±0.41)%,10,50,100,200 mmol·L~(-1)實(shí)驗(yàn)組48 h細(xì)胞增殖抑制率分別為(6.98±0.52)%,(14.36±1.02)%,(24.31±2.06)%,(28.16±2.13)%;10,50,100,200 mmol·L~(-1)實(shí)驗(yàn)組72 h細(xì)胞增殖抑制率分別為(8.96±0.54)%,(23.16±2.45)%,(29.48±2.81)%,(38.49±0.68)%。與對(duì)照組比較,10,50,100,200 mmol·L~(-1)實(shí)驗(yàn)組不同培養(yǎng)時(shí)間HEC1B細(xì)胞的增殖抑制率均顯著升高(P0.01),且HEC1B細(xì)胞的增殖抑制率隨著培養(yǎng)時(shí)間的延長(zhǎng)及藥物濃度的增加而增大(P0.05或P0.01)。內(nèi)皮抑素干預(yù)子宮內(nèi)膜癌HEC1B細(xì)胞72 h后,熒光染色可見(jiàn),與對(duì)照組比較,實(shí)驗(yàn)組細(xì)胞出現(xiàn)細(xì)胞核固縮、細(xì)胞核碎裂、凋亡小體形成及熒光強(qiáng)度增強(qiáng)等凋亡特征。10,50,100,200 mmol·L~(-1)實(shí)驗(yàn)組子宮內(nèi)膜癌HEC1B細(xì)胞培養(yǎng)上清中PARP-1蛋白表達(dá)量低于對(duì)照組,Caspase-3蛋白表達(dá)量明顯高于對(duì)照組(P0.05或P0.01),且呈現(xiàn)一定的濃度依賴性。結(jié)論內(nèi)皮抑素可抑制子宮內(nèi)膜癌HEC1B細(xì)胞的增殖,并促其凋亡,其機(jī)制可能與下調(diào)PARP-1表達(dá)及上調(diào)Caspase-3表達(dá)有關(guān)。
[Abstract]:Objective to study the effect of endostatin on the proliferation of HEC1B cells in endometrial carcinoma. Apoptosis and its effect on the expression of polyadenosine diphosphate polymerase 1 (PARP-1) and cystatin 3 (Caspase-3). Methods HEC1B cells of endometrial carcinoma were treated with endostatin at the final concentration of 1050 ~ 100 mmol 路L ~ (-1). HEC1B cells of endometrial carcinoma without any drug treatment were used as control group. After 48 hours of culture, the proliferation of endometrial carcinoma HEC1B cells was detected by MTT colorimetry, and the apoptosis of endometrial carcinoma HEC1B cells was detected by Hoechst33258 fluorescence staining. The expression of PARP-1 and Caspase-3 in the culture supernatant of endometrial carcinoma HEC1B cells was detected by Elisa. Results the cell proliferation inhibition rates in the control group were 6.24 鹵0.397h, 5.63 鹵0.41g / h, respectively. The inhibitory rates of proliferation in the experimental group were 6.98 鹵0.52h, 14.36 鹵1.02g, 24.31 鹵2.06g / h, 28.16 鹵2.1300200 mmol 路L ~ (-1), respectively.The inhibitory rates of cell proliferation in the experimental group were 14.36 鹵1.02 鹵24.31 鹵2.06 ~ 28.16 鹵2.13100 mmol 路L ~ (-1), respectively. The inhibitory rates of proliferation of HEC1B cells in the experimental group at 72 h were 8.96 鹵0.54 and 23.16 鹵2.45 and 29.48 鹵2.81, respectively. Compared with the control group, the inhibitory rates of proliferation of HEC1B cells in the experimental group were significantly higher than those in the control group, and the inhibition rate of HEC1B cells increased with the prolongation of the culture time and the concentration of drugs. After 72 h of endostatin intervention on HEC1B cells of endometrial carcinoma, Fluorescence staining showed that compared with the control group, the cells in the experimental group showed pyknosis and fragmentation. The expression of PARP-1 protein in the supernatant of HEC1B cell culture of endometrial carcinoma in the experimental group was lower than that in the control group (P0.05 or P0.01), and the expression of PARP-1 protein in the culture supernatant of endometrial carcinoma cells in the experimental group was significantly higher than that in the control group (P0.05 or P0.01A), and the expression of PARP-1 protein in the culture supernatant of endometrial carcinoma cells in the experimental group was significantly higher than that in the control group. Conclusion endostatin can inhibit the proliferation of HEC1B cells in endometrial carcinoma. The mechanism may be related to down-regulation of PARP-1 expression and up-regulation of Caspase-3 expression.
【作者單位】： 安徽醫(yī)科大學(xué)附屬省立醫(yī)院婦產(chǎn)科;
【基金】：安徽省教育廳高校自然科學(xué)研究基金資助項(xiàng)目(KJ2016A482)
【分類號(hào)】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李桃;蔡晶;王澤華;;子宮內(nèi)膜癌淋巴結(jié)轉(zhuǎn)移的術(shù)前評(píng)估[J];婦產(chǎn)與遺傳(電子版);2014年01期

2 劉梅梅;李佩玲;隋麗華;程麗;;內(nèi)皮抑素抑制卵巢癌細(xì)胞生長(zhǎng)的初步研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2008年02期

3 魏增濤,王曉燕,董建春,馬春紅,趙東,張艷,孫汶生;內(nèi)皮抑素真核表達(dá)載體對(duì)移植性卵巢癌的抑制作用[J];中華婦產(chǎn)科雜志;2005年06期

4 李敏;孟會(huì)彥;李紅艷;馮靜;霍琰;;內(nèi)皮抑素對(duì)雌激素刺激下子宮內(nèi)膜癌細(xì)胞增殖的影響研究[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2013年23期

5 宋文杰,史惠蓉;內(nèi)皮抑素在婦科腫瘤的研究進(jìn)展[J];國(guó)外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊(cè);2004年03期

6 劉梅梅;李佩玲;隋麗華;;內(nèi)皮抑素對(duì)人卵巢癌細(xì)胞系生長(zhǎng)的抑制作用[J];基礎(chǔ)醫(yī)學(xué)與臨床;2007年07期

7 黃雙英;張白凌;黃素真;徐惠貞;;子宮內(nèi)膜癌組織中內(nèi)皮抑素的表達(dá)及與血管形成的關(guān)系[J];中國(guó)誤診學(xué)雜志;2009年31期

8 楊莉莉;許倩;;內(nèi)皮抑素在妊娠肝內(nèi)膽汁淤積癥胎盤(pán)中的表達(dá)和意義[J];藥學(xué)與臨床研究;2010年04期

9 程麗;李文輝;劉梅梅;隋麗華;;內(nèi)皮抑素對(duì)宮頸癌細(xì)胞生長(zhǎng)抑制作用的初步研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2007年08期

10 魏增濤,盧愛(ài)英,王曉燕,馬春紅,孫汶生,張艷,朱法良,郭春;內(nèi)皮抑素基因聯(lián)合重組干擾素-α蛋白對(duì)卵巢癌抑制作用的研究[J];實(shí)用婦產(chǎn)科雜志;2005年10期

相關(guān)博士學(xué)位論文 前1條

1 陳雄;攜帶內(nèi)皮抑素基因增殖型腺病毒治療卵巢癌的實(shí)驗(yàn)研究[D];第二軍醫(yī)大學(xué);2006年

相關(guān)碩士學(xué)位論文 前3條

1 徐榕苑;內(nèi)皮抑素聯(lián)合放療治療宮頸癌的研究進(jìn)展[D];重慶醫(yī)科大學(xué);2015年

2 任昀;內(nèi)皮抑素和血管內(nèi)皮生長(zhǎng)因子在宮頸癌組織中的表達(dá)及其生物學(xué)意義[D];鄭州大學(xué);2004年

3 宋文杰;內(nèi)皮抑素和VEGF在卵巢上皮性癌組織中的表達(dá)及其臨床意義[D];鄭州大學(xué);2004年

，

本文編號(hào)：1501494